(PDF) P2.03-10 Gene Mutational Profiling of Chinese

P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1197

Full Text

Open PDF

Abstract

Available in full text

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.02-018 Genomic Profiling of Driver Gene Mutations in 498 Chinese NSCLC Patients

Journal of Thoracic Oncology

English

P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients With Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

English

P3.13-21 Apatinib Plus Icotinib as First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study

Journal of Thoracic Oncology

English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia

English

P2.03-17 EGFR T790M Mutation May Not Be Generated Through Selection by EGFR-TKI From Randomly Occurring Mutations in Vitro Using ENU

Journal of Thoracic Oncology

English

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

Journal of Experimental and Clinical Cancer Research

Cancer Research

Oncology

2017

English

P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations

Journal of Thoracic Oncology

English

P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Journal of Thoracic Oncology

English

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study

Journal of Thoracic Oncology

English

Amanote Research

P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1197

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

P2.02-018 Genomic Profiling of Driver Gene Mutations in 498 Chinese NSCLC Patients

P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients With Advanced NSCLC Harboring EGFR Mutations

P3.13-21 Apatinib Plus Icotinib as First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

P2.03-17 EGFR T790M Mutation May Not Be Generated Through Selection by EGFR-TKI From Randomly Occurring Mutations in Vitro Using ENU

Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines

P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations

P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients With EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/Ii Study